Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$8.6 - $11.9 $26,866 - $37,175
3,124 Added 3.39%
95,242 $964,000
Q4 2023

Feb 14, 2024

SELL
$7.76 - $10.29 $54,327 - $72,040
-7,001 Reduced 7.06%
92,118 $926,000
Q3 2023

Nov 14, 2023

BUY
$9.14 - $24.62 $5,858 - $15,781
641 Added 0.65%
99,119 $928,000
Q2 2023

Aug 14, 2023

BUY
$23.2 - $27.29 $243,716 - $286,681
10,505 Added 11.94%
98,478 $2.42 Million
Q1 2023

May 10, 2023

SELL
$22.26 - $30.85 $49,840 - $69,073
-2,239 Reduced 2.48%
87,973 $2.05 Million
Q4 2022

Feb 14, 2023

BUY
$19.96 - $28.22 $355,168 - $502,146
17,794 Added 24.57%
90,212 $2.28 Million
Q3 2022

Nov 14, 2022

SELL
$18.26 - $31.1 $385,760 - $657,018
-21,126 Reduced 22.58%
72,418 $1.4 Million
Q2 2022

Aug 11, 2022

BUY
$19.08 - $26.7 $1.5 Million - $2.09 Million
78,374 Added 516.64%
93,544 $2.38 Million
Q1 2022

May 16, 2022

BUY
$21.19 - $40.01 $321,452 - $606,951
15,170 New
15,170 $390,000
Q4 2021

Feb 09, 2022

SELL
$30.97 - $54.03 $4.96 Million - $8.65 Million
-160,089 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$34.9 - $54.54 $373,081 - $583,032
-10,690 Reduced 6.26%
160,089 $6.97 Million
Q2 2021

Aug 11, 2021

SELL
$38.75 - $51.0 $1.38 Million - $1.82 Million
-35,637 Reduced 17.26%
170,779 $8.07 Million
Q1 2021

May 07, 2021

SELL
$26.34 - $83.07 $612,036 - $1.93 Million
-23,236 Reduced 10.12%
206,416 $10.6 Million
Q4 2020

Feb 03, 2021

BUY
$25.51 - $43.38 $1.73 Million - $2.93 Million
67,623 Added 41.74%
229,652 $6.15 Million
Q3 2020

Nov 04, 2020

BUY
$28.28 - $53.6 $33,992 - $64,427
1,202 Added 0.75%
162,029 $5.56 Million
Q2 2020

Aug 05, 2020

BUY
$27.89 - $47.86 $4.49 Million - $7.7 Million
160,827 New
160,827 $6.59 Million

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $922M
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.